Livanova Plc's Revenue in the fiscal year 2025 $ 1,387.87 millions
Livanova Plc's Revenue in the fiscal year 2024 $ 1,252.87 millions
Livanova Plc's Revenue in the fiscal year 2023 $ 1,153.25 millions
Livanova Plc's Revenue in the fiscal year 2022 $ 1,021.81 millions
Livanova Plc's Revenue in the fiscal year 2021 $ 1,035.37 millions
LIVN Revenue second quarter 2026 Y/Y Growth Comment
Livanova Plc reported Revenue increase of 10.8% year on year in the second quarter 2026, to $ 390.59 millions, this is lower than Livanova Plc's recent average Revenue improvement of 27.15%.
Looking into second quarter 2026 results within Medical Equipment & Supplies industry 91 other companies have achieved higher Revenue growth. While Livanova Plc' s Revenue growth of 10.8% ranks overall at the positon no. 1646 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Livanova Plc's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
295.69 %
6.88 %
-24.83 %
(Dec 31 2015)
LIVN's II. Quarter Q/Q Revenue Comment
Livanova Plc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 7.97%, to $ 390.59 millions, from $361.75 millions in the first quarter.
Within Medical Equipment & Supplies industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Livanova Plc's Revenue growth quarter on quarter, overall rank is 928.
Livanova Plc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 7.97%, to $ 390.59 millions, from $361.75 millions in the first quarter.
Within Medical Equipment & Supplies industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Livanova Plc's Revenue growth quarter on quarter, overall rank is 928.
Livanova Plc's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 1,470.11
$ 1,432.05
$ 1,387.08
$ 1,349.51
$ 1,309.92
Y / Y Revenue Growth (TTM)
12.23 %
12.29 %
10.71 %
8.86 %
8.42 %
Year on Year Revenue Growth Overall
Ranking
# 1684
# 1639
# 578
# 454
# 907
Seqeuential Revenue Change (TTM)
2.66 %
3.24 %
2.78 %
3.02 %
2.72 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2347
# 2281
# 1110
# 937
# 1505
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Livanova Plc's cumulative twelve months Revenue were $ 1,470 millions, company would post below average annual Revenue growth of 2.72% year on year, if the fiscal year would end at Jun 30 2026. A slow-down in the Livanova Plc's Revenue growth from the 361.75% growth in Mar 31 2026.
In the Healthcare sector 269 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1639 to 1684.
With the quarterly Revenue reported in the Jun 30 2026 period, Livanova Plc's cumulative twelve months Revenue were $ 1,470 millions, company would post below average annual Revenue growth of -13.83% year on year, if the fiscal year would end at Jun 30 2026. A slow-down in the Livanova Plc's Revenue growth from the 361.75% growth in Mar 31 2026.
In the Healthcare sector 269 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1639 to 1684.
About Livanova Plc Revenue Growth Rates (LIVN), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
18.87%